Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06169371 · ClinicalTrials.gov registry record · Phase 4
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
A Phase 4 study of Breast Cancer, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT06169371 is a Phase 4 study of Breast Cancer that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT06169371, a Phase 4 study of Breast Cancer, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers
Conditions Studied
Interventions
- DRUG Abemaciclib
Study Locations (3)
Illinois
- University of Illinois - Chicago
Iowa
- Iowa Holden Comprehensive Cancer Center - Iowa City
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-12-28 |
| Est. Completion | 2030-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06169371
The ClinicalTrials.gov registry entry for NCT06169371 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Abemaciclib is the first listed.
NCT06169371 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Iowa, Ohio.
Frequently Asked Questions
What is clinical trial NCT06169371 about?
NCT06169371 is a clinical study titled "Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)". This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of...
What is the current status of trial NCT06169371?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-12-28. Estimated completion is 2030-11.
What conditions does trial NCT06169371 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06169371?
The interventions under investigation include: Abemaciclib (DRUG).
Who is sponsoring clinical trial NCT06169371?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06169371 being conducted?
This trial has 3 study locations across Illinois, Iowa, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
RECRUITING · Phase 4
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
RECRUITING · Phase 4
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
RECRUITING · Phase 4
-
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.